Updates from the 2024 American Society of Hematology Annual Meeting

The Lymphoma Research Foundation returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 264 Foundation-affiliated scientists, including past and present members of the Foundation’s world-leading Scientific Advisory Board (SAB) and former and current grantees, contributing to an abstract presented at the conference.

Widely regarded as the premier event in malignant and non-malignant hematology, the ASH Meeting provides a critical forum for leading hematologists/oncologists to present their findings to over 20,000 of their peers. Among the distinguished scientists attending, more than 80 Foundation-affiliated scientists presented at the 2024 ASH Annual Meeting.

In addition to the Foundation’s representation through presentations, the Foundation’s researchers contributed to 743 abstracts across all hematology and 698 lymphoma-related abstracts. 100 percent of Foundation scholars — participants in the Foundation’s Lymphoma Scientific Research Mentoring Program (LSRMP) — authored at least one abstract at ASH.

Highlights from ASH 2024:

• Poor Outcomes Observed Following Disease Progression After CD19-Directed CAR T-Cell Therapy
• High Response Rates Observed with Loncastuximab Tesirine Plus Rituximab in High-Risk Patients with Relapsed/Refractory FL
• Phase III Study of Glofitamab Plus Pola-R-CHP Ongoing in Patients with Previously Untreated CD20-Positive LBCL
• High Rates of Disease Control Without Radiotherapy Observed Following Incorporation of Nivolumab in Early Stage cHL
• Interim Results from the AMPLIFY Study Show Durable Responses with Acalabrutinib Plus Venetoclax in Treatment-Naïve CLL
• First-Line Treatment Choice Impacts Risk for Other Malignancies in CLL and SLL
• Real-World Clinical Outcomes With Novel Therapies in Relapsed/Refractory MCL Vary Based on Race and Ethnicity
• Inequitable Patterns in Fertility Counseling Reported by Patients with NHL